This trial is unknown!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Ischemia-reperfusion Injury
and you are
between 18 and 46
years old
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

Ischemia reperfusion injury may be attenuated by HO-1 induction. Heme arginate showed protective effects during prolonged ischemia in animal studies. Functional blood oxygen level dependent (BOLD) magnetic resonance imaging (MRI) shall evaluate the effects of HO-1 induction during short-time ischemia in skeletal muscle of healthy subjects.

Provided treatments

  • Drug: heme arginate administration
  • Drug: Placebo administration

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01461512. The sponsor of the trial is MWolzt and it is looking for 16 volunteers for the current phase.
Official trial title:
The Effects of Intravenous Heme Arginate on Functional Magnetic Resonance Imaging During Ischemia